- Trials with a EudraCT protocol (274)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
274 result(s) found for: Blood clotting.
Displaying page 1 of 14.
EudraCT Number: 2009-018086-12 | Sponsor Protocol Number: BI1412_2009 | Start Date*: 2010-08-23 | ||||||||||||||||||||||||||
Sponsor Name:Athena Care/ Isala Klinieken | ||||||||||||||||||||||||||||
Full Title: Efficacy and safety of Haemocomplettan® P in patients experiencing microvascular bleeding while undergoing elective complex cardiac surgery | ||||||||||||||||||||||||||||
Medical condition: Elective complex cardiac surgery is associated with excessive blood loss due to coagulopathy. Fibrinogen concentrate has been shown to reverse dilutional coagulopathy. In this double blinded, place... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-001872-54 | Sponsor Protocol Number: ARC1779−006 | Start Date*: 2009-01-24 | |||||||||||
Sponsor Name:Archemix Corp | |||||||||||||
Full Title: A Randomized, Double−blind, Placebo−controlled, Clinical Outcome Study of ARC1779 Injection in Patients with Thrombotic Microangiopathy. | |||||||||||||
Medical condition: Thrombotic microangiopathy (TMA) disorders | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000740-21 | Sponsor Protocol Number: LEX-210 | Start Date*: 2022-04-08 | |||||||||||
Sponsor Name:Octapharma AG | |||||||||||||
Full Title: Study of four-factor prothrombin complex concentrate, OCTAPLEX, in patients with acute major bleeding on direct oral anticoagulant (DOAC) therapy with factor Xa inhibitor. | |||||||||||||
Medical condition: Acute major bleeding in patients receiving DOAC therapy with factor Xa inhibitor | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) HR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005650-54 | Sponsor Protocol Number: MD2011.01 | Start Date*: 2012-06-04 | ||||||||||||||||||||||||||
Sponsor Name:University Medical Center Groningen | ||||||||||||||||||||||||||||
Full Title: Prothrombin complex concentrate in the reduction of blood loss during otrhotopic liver transplantation. | ||||||||||||||||||||||||||||
Medical condition: liver cirhosis coagulopathy bleeding | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: FI (Prematurely Ended) NL (Completed) BE (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002727-38 | Sponsor Protocol Number: OMS721-HCT-002 | Start Date*: Information not available in EudraCT | |||||||||||||||||||||
Sponsor Name:Omeros Corporation | |||||||||||||||||||||||
Full Title: A Phase 2 Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Narsoplimab in Paediatric Patients (28 Days to 18 Y.O.) with High Risk Haematopoietic Stem Cell Transplant... | |||||||||||||||||||||||
Medical condition: Thrombotic microangiopathies following haematopoietic stem cell transplant | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Trial now transitioned) ES (Ongoing) HU (Completed) NL (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000246-19 | Sponsor Protocol Number: 3-3002 | Start Date*: 2018-09-24 | ||||||||||||||||
Sponsor Name:Asahi Kasei Pharma America Corporation | ||||||||||||||||||
Full Title: SCARLET-2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of ART-123 in Subjects with Sepsis and Coagulopathy | ||||||||||||||||||
Medical condition: Sepsis, defined by the presence of infection and host inflammation, is a lethal clinical syndrome. In severe disease, the coagulation system becomes diffusely activated, with consumption of multipl... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Prematurely Ended) ES (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001774-23 | Sponsor Protocol Number: 020518-1 | Start Date*: 2018-07-19 |
Sponsor Name:Tampere university hospital | ||
Full Title: Clinical Drug Trial: Efficacy, safety and pharmacokinetics of tinzaparin during Slow Low Efficient Daily Dialysis in Intensive Care Patients | ||
Medical condition: Patients with clinical indication for pharmacological thromboprophylaxis and slow low efficient daily dialysis (SLEDD). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2017-000485-29 | Sponsor Protocol Number: STH19752 | Start Date*: 2017-05-23 |
Sponsor Name:Dr | ||
Full Title: Prolonged ENoxapariN in primarY Percutaneous Coronary Intervention; a Pilot Pharmacodynamic study (PENNY PCI study) | ||
Medical condition: ST elevation myocardial infarction. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-005298-29 | Sponsor Protocol Number: NL75820.100.20 | Start Date*: 2021-03-16 |
Sponsor Name:St. Antonius Hospital | ||
Full Title: Monitoring the effect of oral anticoagulants during percutaneous coronary intervention | ||
Medical condition: Anticoagulation during percutaneous coronary intervention | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2009-009116-49 | Sponsor Protocol Number: HES | Start Date*: 2009-05-04 |
Sponsor Name:ISTITUTO GIANNINA GASLINI | ||
Full Title: Study on efficacy of Tetraspan on children aged less than 36 months undergoing major surgery | ||
Medical condition: Major surgery | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-004024-11 | Sponsor Protocol Number: SHP648-101 | Start Date*: 2020-05-04 | |||||||||||
Sponsor Name:Baxalta Innovations GmbH | |||||||||||||
Full Title: An Open-Label, Multinational, Phase 1/2 Study of the Safety and Dose Escalation of SHP648, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing FIX Padua in Hemophilia B Subjects | |||||||||||||
Medical condition: Hemophilia B is a X-linked recessive bleeding disorder caused by mutations in the gene encoding clotting factor IX (FIX) that result in disruption of the normal clotting pathway. Hemophilia B affec... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Prematurely Ended) HU (Prematurely Ended) ES (Prematurely Ended) AT (Prematurely Ended) FR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002211-65 | Sponsor Protocol Number: GIS-2021-JAKihemo | Start Date*: 2021-08-13 | |||||||||||||||||||||
Sponsor Name:Fundación Española de Gastroenterología | |||||||||||||||||||||||
Full Title: EFFECT OF TOFACITINIB ON COAGULATION AND PLATELET FUNCTION, AND ITS ROLE IN THROMBOEMBOLIC EVENTS | |||||||||||||||||||||||
Medical condition: ulcerative colitis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003599-38 | Sponsor Protocol Number: 261201 | Start Date*: 2013-09-17 | |||||||||||
Sponsor Name:Baxter Innovations GmbH | |||||||||||||
Full Title: A Phase 2/3, Multi-Center, Open Label Study of Efficacy, Safety, and Pharmacokinetics of PEGylated Recombinant Factor VIII (BAX 855) Administered for Prophylaxis and Treatment of Bleeding in Previo... | |||||||||||||
Medical condition: Severe hemophilia A (FVIII <1%) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) AT (Completed) LT (Completed) CZ (Completed) SE (Completed) ES (Completed) BE (Completed) NL (Completed) BG (Completed) PL (Completed) HU (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005014-30 | Sponsor Protocol Number: AlproECMO_1.0 | Start Date*: 2016-06-02 | ||||||||||||||||
Sponsor Name:Medical University of Vienna, Department of Internal medicine I | ||||||||||||||||||
Full Title: A prospective randomized, double blind study on safety and efficacy of Alprostadil as additional Anticoagulant in Patients with veno- venous ECMO | ||||||||||||||||||
Medical condition: pulmonary insufficiency, which cannot be treated with measures of mechanical ventilation alone, Conditions in which veno-venous extracorporeal membrane oxygenation therapy is indicated | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-000909-24 | Sponsor Protocol Number: 201302-OPTICLOT | Start Date*: 2013-08-29 | |||||||||||||||||||||
Sponsor Name:Erasmus MC | |||||||||||||||||||||||
Full Title: "OPTI-CLOT": Peri-Operative PharmacokineTIc-guided dosing of CLOTting factor in Hemophilia. | |||||||||||||||||||||||
Medical condition: Hemophillia | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male | ||||||||||||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-002136-40 | Sponsor Protocol Number: 261203 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Baxalta Innovations GmbH | |||||||||||||
Full Title: Phase 3, prospective, multi-center, open label study to investigate safety, immunogenicity, and hemostatic efficacy of PEGylated Factor VIII (BAX 855) in previously untreated patients (PUPs) < 6 y... | |||||||||||||
Medical condition: Severe hemophilia A (FVIII <1%) | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BG (Prematurely Ended) ES (Completed) CZ (Prematurely Ended) AT (Completed) HU (Completed) DE (Completed) NL (Prematurely Ended) BE (Completed) NO (Completed) DK (Completed) FI (Completed) IT (Completed) Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005273-23 | Sponsor Protocol Number: 923 | Start Date*: 2012-01-30 | |||||||||||
Sponsor Name:Liverpool Heart and Chest Hospital | |||||||||||||
Full Title: HEAT-PPCI - How Effective are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention - A randomised controlled trial to compare unfractionated heparin versus bivalirudin in the trea... | |||||||||||||
Medical condition: ST elevation myocardial infarction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004357-13 | Sponsor Protocol Number: CTH201401 | Start Date*: 2015-03-18 | |||||||||||
Sponsor Name:Odense University Hospital | |||||||||||||
Full Title: Coagaulation in patients with atrial fibrillation: The effect of dabigatran | |||||||||||||
Medical condition: Atrial fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001456-34 | Sponsor Protocol Number: ArgatrobanECMO_1.2 | Start Date*: 2021-07-08 |
Sponsor Name:Medical University of Vienna | ||
Full Title: A prospective randomized pilot trial on safety and feasibility of Argatroban as anticoagulant in patients with extracorporeal membrane oxygenation (ECMO) | ||
Medical condition: patients requiring treatment with extracorporeal membrane oxygenation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: View results |
EudraCT Number: 2004-000219-24 | Sponsor Protocol Number: 3082A-101342 | Start Date*: 2005-04-28 |
Sponsor Name:Wyeth Pharmaceuticals | ||
Full Title: A multicentre study to describe the immunogenic epitope(s) of factor VIII in previously treated patients with congenital haemophilia A who develop de novo factor VIII inhibitors while receiving fac... | ||
Medical condition: Haemophilia A is an X-linked recessive clotting disorder in which the clotting factor, factor VIII (FVIII), is deficient or inactive. Patients with low levels of FVIII have an increased tendency t... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) BE (Completed) ES (Completed) DE (Prematurely Ended) IT (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
